Baseline Baseline Follow-up Follow-up
Study outcomes r P-value r P-value
Efficacy and safety 0.013 0.914 0.018 0.885
Efficacy and adherence§ 0.194 0.106 -0.043 0.721
Efficacy and satisfaction 0.164 0.171 0.021 0.865
Efficacy and QoL -.055 0.646 -0.178 0.137
Safety and adherence§ -0.06 0.62 -0.214 0.074
Safety and satisfaction -0.112 0.354 -0.263 <0.05*
Safety and QoL -0.723 <0.0001** -0.782 <0.0001**
Adherence§ and satisfaction 0.173 0.15 0.682 <0.0001**
Adherence§ and QoL -.063 0.6 0.323 <0.01**
Satisfaction and QoL -.053 0.66 0.298 <0.05*
† Number of seizures ‡ Pediatric epilepsy side effects questionnaire score § Morisky medication adherence score ¶ Satisfaction with information about medicines score * statistically significant (Pearson correlation test) at the level of P -value <0.05 ** statistically significant (Pearson correlation test) at the level ofP -value <0.01
Table 4 Significant correlation between the study outcomes and patients’ demographic and clinical characteristics
Study Outcome Baseline QoL Follow-up QoL Baseline safety Follow-up safety Follow-up efficacy
Variable
Age r=-0.413 - - - -
P-value <0.0001**
Siblings with epilepsy r=-0.276 - - - -
P-value < 0.05*
Number of medications r=-0.421 r=-0.409 r=0.318 r=0.259 r=0.240
P-value <0.0001** P-value <0.0001** P-value <0.01** P-value <0.05** P-value <0.05**